Primary and secondary drug treatment of myocardial infarction.
The management of myocardial infarction has been revolutionized during the last few years. Based on a better understanding of the physiopathology of infarction, aggressive intervention with drug therapy has made great reductions in both mortality and morbidity possible. Early reperfusion of the infarct-related artery with such thrombolytic agents as streptokinase or recombinant tissue plasminogen activator may decrease acute mortality by up to 50%. New uses for older drugs, such as acetylsalicylic acid and nitroglycerin, give them a primary role in acute myocardial infarction. β-Blocking drugs, when given in the early and later phases of myocardial infarction, also clearly reduce mortality and morbidity. Combining early reperfusion and adjunctive therapy with ASA, nitrates, and β-blockers will surely become accepted as the most effective method of treating the pain, limiting the damage, and preventing the complications of myocardial infarction.
J W
JW
Warnica
N Engl J Med. 1986 Aug 14;315(7):423-9
3526151
Br Heart J. 1989 Jan;61(1):9-13
2563657
Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71
2858114
Lancet. 1988 May 14;1(8594):1088-92
2896919
Circulation. 1988 Oct;78(4):906-19
3139326
Ann Intern Med. 1989 Jun 15;110(12):957-62
2658715